

Michelle Haber

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8156288/michelle-haber-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

6,639
citations

45
h-index

76
g-index

173
ext. papers

7,811
ext. citations

8.4
avg, IF

5.31
L-index

#	Paper	IF	Citations
164	ABC transporters in cancer: more than just drug efflux pumps. <i>Nature Reviews Cancer</i> , 2010 , 10, 147-56	31.3	769
163	Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. <i>New England Journal of Medicine</i> , 1996 , 334, 231-8	59.2	256
162	ABC transporters as mediators of drug resistance and contributors to cancer cell biology. <i>Drug Resistance Updates</i> , 2016 , 26, 1-9	23.2	237
161	Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. <i>Blood</i> , 2004 , 103, 3905-14	2.2	194
160	ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. <i>Cancer Research</i> , 2008 , 68, 9735-45	10.1	158
159	The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. <i>Blood</i> , 2002 , 99, 4100-8	2.2	158
158	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. <i>Nature Medicine</i> , 2010 , 16, 1134-40	50.5	156
157	Role of the MRP1/ABCC1 multidrug transporter protein in cancer. <i>IUBMB Life</i> , 2007 , 59, 752-7	4.7	148
156	Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1546-53	2.2	135
155	The p53 pathway and its inactivation in neuroblastoma. <i>Cancer Letters</i> , 2003 , 197, 93-8	9.9	125
154	Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 12664-9	11.5	118
153	SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. <i>PLoS Genetics</i> , 2011 , 7, e1002135	6	117
152	Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. <i>Journal of Biological Chemistry</i> , 1995 , 270, 31269-75	5.4	113
151	Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 547-53	6.1	112
150	Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. <i>Chemistry and Biology</i> , 2003 , 10, 597-607		102
149	ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1236-51	9.7	98
148	The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. <i>Oncotarget</i> , 2014 , 5, 1793-804	3.3	91

147	MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3604-13	2.2	90
146	Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 18682-7	11.5	88
145	The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. <i>Oncotarget</i> , 2016 , 7, 8663-75	3.3	88
144	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <i>Science Translational Medicine</i> , 2015 , 7, 312ra176	17.5	86
143	Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 1394-403	9.7	86
142	Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. <i>Blood</i> , 2007 , 110, 632-9	2.2	84
141	ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	79
140	Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. <i>Cancer Research</i> , 2009 , 69, 6573-80	10.1	79
139	Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 19532-43	5.4	71
138	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. <i>Nature Medicine</i> , 2020 , 26, 1742-1753	50.5	69
137	MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. <i>Oncogene</i> , 2004 , 23, 753-62	2	68
136	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. <i>Cancer Research</i> , 2017 , 77, 971-981	10.1	64
135	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. <i>International Journal of Cancer</i> , 1996 , 65, 613-9	7.5	62
134	Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. <i>British Journal of Cancer</i> , 2018 , 119, 693-696	8.7	62
133	Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	55
132	Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015 , 168, 395-404	4.5	54
131	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019 , 19, 420-438	31.3	52
130	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. <i>Cell Reports</i> , 2019 , 29, 1675-1689.e9	10.6	51

129	p53 determines multidrug sensitivity of childhood neuroblastoma. <i>Cancer Research</i> , 2007 , 67, 10351-60	10.1	51
128	Too many targets, not enough patients: rethinking neuroblastoma clinical trials. <i>Nature Reviews Cancer</i> , 2018 , 18, 389-400	31.3	50
127	Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. <i>Translational Pediatrics</i> , 2015 , 4, 226-38	4.2	50
126	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. <i>Cancer</i> , 2017 , 123, 1095-1105	6.4	48
125	Maternal folate and other vitamin supplementation during pregnancy and risk of acute lymphoblastic leukemia in the offspring. <i>International Journal of Cancer</i> , 2010 , 126, 2690-9	7.5	47
124	Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. <i>Oncogene</i> , 1998 , 17, 751-9	9.2	47
123	Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. <i>Clinical Cancer Research</i> , 2016 , 22, 4391-404	12.9	47
122	Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2009 , 146, 292-9	4.5	46
121	Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. <i>American Journal of Pathology</i> , 1999 , 155, 17-21	5.8	46
120	Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. <i>Cell Reports</i> , 2017 , 19, 2544-2556	12.56	45
119	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). <i>Biochemical Pharmacology</i> , 2014 , 91, 97-108	6	41
118	The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. <i>Nature Communications</i> , 2019 , 10, 5026	17.4	40
117	Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 704-9	2.2	40
116	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013 , 131, 8-14	4.9	39
115	Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. <i>Journal of Biological Chemistry</i> , 2010 , 285, 3561-3567	5.4	39
114	Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 6209-16	8.3	37
113	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. <i>European Journal of Cancer</i> , 2009 , 45, 1846-54	7.5	37
112	c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. <i>Molecular Cancer Research</i> , 2011 , 9, 1054-66	6.6	37

111	Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. <i>Frontiers in Oncology</i> , 2012 , 2, 162	5.3	37
110	GPR84 sustains aberrant Eatenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis. <i>Blood</i> , 2014 , 124, 3284-94	2.2	35
109	Molecular profiling of childhood cancer: Biomarkers and novel therapies. <i>BBA Clinical</i> , 2014 , 1, 59-77		32
108	The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. <i>Journal of Pathology</i> , 2012 , 226, 451-62	9.4	32
107	P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. <i>International Journal of Cancer</i> , 1998 , 78, 176-81	7.5	32
106	Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. <i>European Journal of Cancer</i> , 2007 , 43, 1467-75	7.5	32
105	A simple method for the isolation of genomic DNA from mouse tail free of real-time PCR inhibitors. <i>Journal of Proteomics</i> , 2002 , 52, 145-9		31
104	High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. <i>Cancer Letters</i> , 2016 , 374, 315-23	9.9	30
103	Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1635-45	7.4	30
102	Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth. <i>Oncotarget</i> , 2016 , 7, 47479-47493	3.3	30
101	JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. <i>Nature Communications</i> , 2019 , 10, 3319	17.4	29
100	Macrophage-Derived IL1 β and TNF α Regulate Arginine Metabolism in Neuroblastoma. <i>Cancer Research</i> , 2019 , 79, 611-624	10.1	29
99	Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. <i>Cancer Research</i> , 2018 , 78, 3122-3134	10.1	28
98	Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2264-71	2.2	27
97	The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. <i>Cancer Letters</i> , 2009 , 277, 82-90	9.9	26
96	ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. <i>Frontiers in Oncology</i> , 2012 , 2, 178	5.3	25
95	The estrogen-responsive B box protein is a novel regulator of the retinoid signal. <i>Journal of Biological Chemistry</i> , 2006 , 281, 18246-56	5.4	25
94	Mechanism of relapse in pediatric acute lymphoblastic leukemia. <i>Cell Cycle</i> , 2008 , 7, 1315-20	4.7	24

93	Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. <i>Oncotarget</i> , 2014 , 5, 4257-68	3.3	24
92	A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children. <i>British Journal of Haematology</i> , 2018 , 180, 550-562	4.5	23
91	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2020 , 38, 263-278.e6	24.3	22
90	Enhancing the anti-angiogenic action of histone deacetylase inhibitors. <i>Molecular Cancer</i> , 2007 , 6, 68	42.1	22
89	The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. <i>Cancer Letters</i> , 2005 , 228, 241-6	9.9	22
88	Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. <i>Blood Cells, Molecules, and Diseases</i> , 2002 , 29, 1-13	2.1	22
87	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. <i>Scientific Reports</i> , 2014 , 4, 4669	4.9	20
86	Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 709-17	1.9	20
85	Retinoic acid receptors beta and gamma distinguish retinoid signals for growth inhibition and neuritogenesis in human neuroblastoma cells. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 229, 349-54	3.4	20
84	Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. <i>British Journal of Cancer</i> , 2020 , 122, 680-691	8.7	20
83	MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. <i>Cancer Research</i> , 2016 , 76, 3604-17	10.1	20
82	JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. <i>Leukemia</i> , 2019 , 33, 1400-1410	10.7	20
81	TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013 , 18, 639-51	5.4	19
80	ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 270-9	1.9	19
79	Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 302, 462-8	3.4	19
78	Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 6353-68	3.3	19
77	Intratatumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. <i>Cancer Research</i> , 2020 , 80, 4129-4144	10.1	19
76	ABC transporters and neuroblastoma. <i>Advances in Cancer Research</i> , 2015 , 125, 139-70	5.9	18

75	Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma. <i>Clinical Cancer Research</i> , 2012 , 18, 5690-700	12.9	18
74	Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. <i>Molecular Oncology</i> , 2016 , 10, 866-78	7.9	18
73	Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. <i>Cancer Research</i> , 2019 , 79, 5652-5667	10.1	17
72	Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. <i>Nature Communications</i> , 2021 , 12, 971	17.4	17
71	Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. <i>Journal of Proteomics</i> , 2014 , 96, 1-12	3.9	16
70	The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. <i>Carcinogenesis</i> , 2009 , 30, 1865-71	4.6	16
69	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. <i>Oncotarget</i> , 2016 , 7, 1960-72	3.3	16
68	Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. <i>Cancer Biology and Therapy</i> , 2018 , 19, 1078-1087	4.6	16
67	MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. <i>Biochemical Pharmacology</i> , 2019 , 168, 237-248	6	15
66	Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan <i>in vivo</i> . <i>European Journal of Cancer</i> , 2017 , 83, 132-141	7.5	15
65	Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993 , 119, 315-7	4.9	15
64	Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 48-56	4	14
63	Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease. <i>PLoS ONE</i> , 2013 , 8, e76455	3.7	14
62	Growth inhibitory retinoid effects after recruitment of retinoid X receptor beta to the retinoic acid receptor beta promoter. <i>International Journal of Cancer</i> , 2003 , 105, 856-67	7.5	14
61	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. <i>Oncotarget</i> , 2016 , 7, 79217-79232	3.3	14
60	Thymosin- β 4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. <i>Molecular Oncology</i> , 2015 , 9, 1484-500	7.9	13
59	Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines. <i>BMC Cancer</i> , 2008 , 8, 259	4.8	13
58	Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction. <i>British Journal of Haematology</i> , 2000 , 109, 430-4	4.5	13

57	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. <i>Leukemia</i> , 2020 , 34, 1828-1839	10.7	13
56	Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. <i>International Journal of Cancer</i> , 2020 , 146, 1902-1916	7.5	13
55	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. <i>Oncogene</i> , 2019 , 38, 3824-3842	9.2	12
54	Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2654-63	6.1	12
53	Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 165, 1435-41	3.4	12
52	MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. <i>Oncotarget</i> , 2016 , 7, 54937-54951	3.3	12
51	Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. <i>Journal of Molecular Diagnostics</i> , 2009 , 11, 194-200	5.1	11
50	Regions syntenic to human 17q are gained in mouse and rat neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 2004 , 40, 158-63	5	11
49	MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. <i>Oncotarget</i> , 2015 , 6, 15510-23	3.3	11
48	Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition. <i>Oncogene</i> , 2020 , 39, 3555-3570	9.2	10
47	N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. <i>Cancer Research</i> , 2012 , 72, 845-53	10.1	10
46	Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2. <i>Cancer</i> , 1991 , 68, 981-7	6.4	9
45	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2020 , 34, 1524-1539	10.7	9
44	Therapy-induced drug resistance in a human leukemia line (LALW-2). A clinically relevant model. <i>Cancer</i> , 1989 , 63, 2103-10	6.4	8
43	Sizing of DNA fragments by preparative, benzoylated DEAE-cellulose chromatography. <i>FEBS Letters</i> , 1981 , 133, 72-4	3.8	8
42	CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. <i>Oncotarget</i> , 2016 , 7, 46067-46087	3.3	8
41	Targeted Therapy of -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 1438-1451	12.9	8
40	A xenograft model of infant leukaemia reveals a complex MLL translocation. <i>British Journal of Haematology</i> , 2008 , 140, 716-9	4.5	7

39	Patterns of structural change in DNA during tissue necrosis indicated by benzoylated DEAE-cellulose chromatography. <i>Chemico-Biological Interactions</i> , 1985 , 53, 247-55	5	7
38	Single-strand-specific degradation of DNA during isolation of rat liver nuclei. <i>Biochemistry</i> , 1985 , 24, 5803-9	3.9	7
37	Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky047	4.6	7
36	miR-101 suppresses the development of -rearranged acute myeloid leukemia. <i>Haematologica</i> , 2019 , 104, e296-e299	6.6	6
35	Synergy between 5Tand 3Tflanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells. <i>Neuroscience Letters</i> , 2000 , 292, 147-50	3.3	6
34	Limitations on the stability of benzoylated DEAE-cellulose. <i>Analytical Biochemistry</i> , 1984 , 139, 363-6	3.1	6
33	Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.. <i>Drug Resistance Updates</i> , 2021 , 100795	23.2	6
32	Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. <i>British Journal of Cancer</i> , 2021 , 125, 55-64	8.7	6
31	ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2020 , 147, 2225-2238	7.5	5
30	Folate pathway gene polymorphisms and risk of childhood brain tumors: results from an Australian case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 931-7	4	5
29	Dose-dependent persistence of alkylation-induced single stranded regions in rat liver DNA in vivo. <i>Cancer Letters</i> , 1985 , 28, 27-33	9.9	5
28	Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia. <i>Leukemia</i> , 2021 , 35, 3101-3112	10.7	5
27	MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2018 , 1861, 235-245	6	4
26	Sensitive non-radioactive PCR detection of clonal T-cell receptor-gamma gene rearrangements in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1997 , 98, 995-8	4.5	4
25	Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. <i>Cell Reports</i> , 2021 , 35, 108994	10.6	4
24	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. <i>Cancer Research</i> , 2020 , 80, 3706-3718	10.1	3
23	Two-stage incorporation of thymidine triphosphate into mammalian DNA as indicated by chromatography on benzoylated DEAE-cellulose. <i>Biomedical Applications</i> , 1986 , 382, 127-34		3
22	A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. <i>Oncogene</i> , 2021 , 40, 2367-2381	9.2	3

21	Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy. <i>ImmunoTargets and Therapy</i> , 2021 , 10, 123-140	9	3
20	The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. <i>Molecular Oncology</i> , 2021 , 15, 1162-1179	7.9	3
19	Transcriptome profiling of caspase-2 deficient EMyC and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling. <i>Cell Death and Disease</i> , 2019 , 10, 56	9.8	2
18	Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28133	3	2
17	Recurrent fusions in pediatric sarcoma and brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020 , 6,	2.8	2
16	An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro. <i>Cancer Letters</i> , 1995 , 97, 49-55	9.9	1
15	Methodological advances in the discovery of novel neuroblastoma therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2021 , 1-13	6.2	1
14	Targeting Multidrug Resistance in Neuroblastoma. <i>Pediatric Cancer</i> , 2012 , 115-123		1
13	CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. <i>Biochemical Pharmacology</i> , 2020 , 172, 113770	6	1
12	Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in -Rearranged Ph-like ALL. <i>Molecular Cancer Research</i> , 2020 , 18, 1767-1776	6.6	1
11	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , 2021 , 13,	6.6	1
10	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. <i>British Journal of Cancer</i> , 2021 ,	8.7	1
9	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate 1996 , 65, 613		1
8	Donor T cells for CAR T cell therapy.. <i>Biomarker Research</i> , 2022 , 10, 14	8	1
7	In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.. <i>EMBO Molecular Medicine</i> , 2021 , e14608	12	1
6	Systematic Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.. <i>Frontiers in Oncology</i> , 2021 , 11, 779859	5.3	0
5	Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. <i>Cell Death and Disease</i> , 2021 , 12, 268	9.8	0
4	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4338-4352	12.9	0

- 3 A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma. *Current Protocols*, **2021**, 1, e310
- 2 Cell-based methods for the identification of MYC-inhibitory small molecules. *Methods in Molecular Biology*, **2013**, 1012, 255-64 1.4
- 1 Cell-Based Methods for the Identification of Myc-Inhibitory Small Molecules. *Methods in Molecular Biology*, **2021**, 2318, 337-346 1.4